Manganese superoxide dismutase (MnSOD) has been shown to suppress the development of cancer. Tamoxifen (TAM), a nonsteroidal anti-estrogen that is widely used in chemotherapy, is known to be a modulator of antioxidant status. However, the mechanism by which TAM mediates antioxidant enzyme induction remains unclear. In this study we investigated TAM enhancement of MnSOD induction by TNF-a. The results show that co-treatment with TAM and TNF-a increases the MnSOD promoter/enhancer driven luciferase activity, MnSOD mRNA and protein levels. Interestingly, cotreatment with TAM and TNF-a drastically decreases the binding activity of the p50/p50 homodimer and increases that of the p50/p65 heterodimer compared to TNF-a alone. This change in DNA binding could not be attributed to a decrease in the level of p50, its precursor, p105, or its inhibitors. Furthermore, TAM did not enhance degradation of IkB-a. These results suggest that p50/p50 homodimer may act as an inhibitory complex of MnSOD expression. Modulation of the DNA binding activity in favor of the p50/p65 complex may enhance NF-kB mediated induction of MnSOD by TAM. These ®ndings reveal a potential novel mechanism for the induction of the human MnSOD gene.
Introduction
Reactive oxygen species (ROS) are by-products of aerobic metabolism. ROS are involved in the pathogenesis of many diseases (Halliwell, 1996) , including signaling cell transformation (Cerutti, 1985) . A variety of antioxidant enzymes protect cells from injury by ROS. Manganese superoxide dismutase (MnSOD) is an essential mitochondrial antioxidant enzyme that dismutates superoxide radicals into hydrogen peroxide and molecular oxygen (Weisiger and Fridovich, 1973) . Overexpression of MnSOD has been shown to reduce radiation-induced neoplastic transformation (St.Clair et al., 1992) , and suppress tumor formation in a multistage skin carcinogenesis model (Zhao et al., 2001) . In addition, accumulating data suggest that MnSOD might function as a new type of tumor suppressor gene (see St.Clair, 1996 for a review). Thus, understanding the mechanisms of MnSOD induction may lead to development of speci®c measures to increase the MnSOD levels to prevent cancer development and increase the cure rate of cancer.
Tumor necrosis factor-a (TNF-a), a proin¯amma-tory cytokine, can induce MnSOD levels in mammalian cells both in vivo and in vitro (Wong and Goeddel, 1988) . The gene regulatory eects of TNF-a on MnSOD appear to be mediated through the activation of the transcription factor NF-kB (Xu et al., 1999) .
Nuclear factor kB (NF-kB) is a cytokine-inducible transcription factor that plays an essential role in a variety of physiological processes including in¯amma-tory responses, stress, immune responses, apoptosis, and cellular proliferation (Baeuerle and Henkel, 1994; Wulczyn et al., 1996; Barnes and Karin, 1997; Ghosh et al., 1998) . This family consists of ®ve members: p50, p65 (Rel A), p52, c-Rel and Rel B which share conserved DNA-binding and dimerization domains and forms various homo-and heterodimers (see Siebenlist et al., 1994; Miyamoto and Verma, 1995 for reviews) . NF-kB is normally sequestered in the cytoplasm by association with members of the IkB protein family which bind NF-kB and mask its nuclear localization signal. Upon stimulation by dierent agents, IkB molecules are rapidly phosphorylated and degraded, allowing the NF-kB dimers to translocate to the nucleus and regulate transcription through binding to the kB site (Gilmore, 1999; Karin and Ben-Neriah, 2000) .
NF-kB dimers dier in their binding anities for kB sites and in their abilities to activate transcription. Only p65/Rel A and c-Rel contain a potent transcrip-tional-activation domain. Dimers composed solely of Rel proteins that lack transcriptional-activation domains such as p50, likely mediate transcriptional repression (Urban and Baeuerle, 1990; Miyamoto and Verma, 1995) .
Tamoxifen (TAM), a synthetic nonsteroidal antiestrogen, has been used widely in the treatment of both advanced and early-stage breast cancer (Love, 1989) . Although the mechanism of TAM's antitumor activity remains unclear, the preferential blocking of estrogen binding to the estrogen receptor (ER) appears important in preventing estrogen stimulated growth. However, TAM has also been shown to be cytotoxic to ER-negative cells (Goldenburg and Froses, 1982; Taylor et al., 1984) , suggesting that at least a part of the antineoplastic action may be independent of its anti-hormone properties. In addition, increased levels of enzymatic and nonenzymatic antioxidants have been reported in TAM-treated postmenopausal women with breast cancer compared with baseline values (Thangaraju and Vijayalakshmi, 1994) . Thus, it is possible that TAM may provide anti-neoplastic action by enhancing the induction of endogenous antioxidant enzymes.
Considering MnSOD as a new type of tumor suppressor gene as well as the properties of TAM that can enhance endogenous antioxidant levels in cancer patients, we investigated the mechanisms by which TAM modulates MnSOD expression in an SV-40 transformed human lung ®broblast (VA-13) and an estrogen receptor positive human breast cancer (MCF-7) cell line.
Results

Combination treatment by TAM and TNF-a enhances TNF-a mediated MnSOD mRNA and protein levels
To determine whether the endogenous human MnSOD gene was responsive to the treatments, VA-13 cells were treated with TNF-a (200 U/ml) alone, TAM (10 ± 20 mM) alone, or in combination. RNA was isolated after treatment with TAM for 24 h followed by TNF-a treatment for 6 h. Hybridization with a human MnSOD cDNA probe showed that mRNA levels increased following TNF-a treatment but not after treatment with TAM alone. The levels of MnSOD mRNA were higher after the combination treatment of TAM and TNF-a than TNF-a alone (Figure 1a ). This result was observed with both the 4 kb and 1 kb transcripts. The blot was stripped and reprobed with a chicken b-actin cDNA probe as a control for RNA integrity and loading. The 4 kb and 1 kb mRNA level increased an average of 2 and 3 fold respectively, in the TNF-a treated cells. The combination of TAM/TNF-a enhanced the 4 kb and 1 kb transcripts by 4 and 6 fold, 4.5-and 7.5-fold, 5.5-and 8 fold with 10, 15 and 20 mM TAM/TNF-a respectively.
To determine the MnSOD protein levels in VA-13, cells were collected after treatment and MnSOD protein levels were detected by Western blotting. The results showed that TNF-a increased MnSOD protein levels ®vefold within 12 h compared to the non-treated control; however, the levels of MnSOD protein were not aected by TAM treatment alone. Combination treatment increased MnSOD protein levels by 14-fold ( Figure 1b) . These levels are consistent with the increase in the MnSOD mRNA levels.
To verify that the eect of TAM and TNF-a is not speci®c to ®broblast cells, the MnSOD protein and mRNA levels in the MCF-7 cells were studied after TNF-a and TAM treatments. The results demonstrated that TNF-a increased the levels of the MnSOD mRNA ( Figure 2a ) and protein (Figure 2b ), and these levels were further increased in the combination treatment. In MCF-7 cells, the induction of MnSOD in the combination treatment was detectable at all concentrations of TAM from 1 ± 15 mM (Figure 2 ).
The enhancer element within the second intron of the human MnSOD gene is responsive to the induction by a combination of TAM and TNF-a
Previous results from our laboratory demonstrated that an enhancer element within the second intron of the human MnSOD gene is essential for TNF-a-mediated MnSOD induction (Xu et al., 1999) . To identify whether this element could respond to a combination treatment of TAM and TNF-a, VA-13 cells stably transfected with the intronic enhancer element of the human MnSOD gene (C7) were used. As illustrated in Figure 3 , the intronic enhancer element of the human MnSOD gene responds to the combination of TAM and TNF-a in a TAM dose-dependent manner but the transcription activity was not aected by TAM alone.
Decreased DNA binding of p50/p50 homodimer in VA-13 treated with combination of TAM and TNF-a
The intronic enhancer contains an NF-kB, an NF-1 and multiple C/EBP binding sites. Therefore we examined the binding of these proteins to DNA after treatment with TAM alone, TNF-a alone or in combination. The increase of both the p50/p65 heterodimer and p50/p50 homodimer NF-kB DNA binding activity was observed following TNF-a treatment ( Figure 4 ). An increase of p50/p65 heterodimer and a decrease of p50/p50 homodimer DNA binding activity was found in combination treatment of TAM and TNF-a but no change of NF-kB DNA-binding (p50/p50 or p50/p65) was found in TAM treatment alone ( Figure 4 ). No change in the DNA-binding of NF-1 and C/EBP was found after treatment with TAM alone, TNF-a alone or in combination (data not shown). The identities of the p65 and p50 in each homo-and heterodimer complex were veri®ed by supershift assays.
The potential of TAM for p50 inhibitor activation
Because p50/p50 homodimer DNA binding activity was decreased in a combination treatment between TAM and TNF-a compared to TNF-a treatment alone, the potential of TAM activation of p50/p50 homodimer inhibitors was investigated. We reasoned that if TAM was able to activate unknown inhibitors of p50/ p50 homodimer in nuclear extracts, the addition of nuclear extracts obtained from TNF-a-treated and Cells were treated with either 200 U/ml of TNF-a for 12 h alone, 1 ± 15 mM TAM for 24 h alone or in combination (TAM+TNF-a) by pretreatment with TAM for 24 h followed by TNF-a for 12 h. Protein of each sample was electrophoresed, electrotransferred, and then immunologically stained for human MnSOD Figure 3 Transcription study. VA-13 cells stably expressing a luciferase reporter gene under the control of the human MnSOD promoter and enhancer elements were treated with 1 ± 15 mM TAM for 24 h followed by 200 U/ml TNF-a for 12 h. The average luciferase activities from three separate experiments is illustrated (mean+s.d.) (*P-value 5 0.05) (Signi®cant dierence between TNF-a treatment and combination of TAM and TNF-a)
Figure 4 NF-kB DNA-binding activity in VA-13 cells. Nuclear proteins (5 mg) from untreated or treated cells were analysed on EMSA with labeled NF-kB probe (lanes 1 ± 4). Antibody raised against either the p50 NF-kB subunit (lanes 5 ± 8) or the p65 NFkB subunit (lanes 9 ± 12) were added to the extracts before the addition of the probe Oncogene Tamoxifen enhances TNF-a induction of MnSOD C Daosukho et al from TAM-treated cells might lead to loss of the p50/ p50 homodimer binding activity compared to nuclear extract from untreated and TNF-a treated cells. To examine whether TAM could activate a p50/p50 homodimer inhibitor, we combined nuclear extracts and measured NF-kB binding activities using EMSA (Figure 5a ). We did not observe a decrease of p50/p50 homodimers in the combination of nuclear extracts from TNF-a treated and TAM treated cells ( Figure  5a ).
DOC could not recover the p50/p50 homodimer DNA binding
It has been shown that dissociating agents, such as the anionic detergent, deoxycholate (DOC) is able to release NF-kB from IkB in cytosolic extracts and allow NF-kB to bind DNA. We tested whether potential`unknown' protein inhibitors were involved in the decrease of p50/p50 homodimer binding to the NF-kB site by treating nuclear extracts obtained from either TNF-a or a combination of TAM and TNF-a treatment with DOC. The results showed that DOC could not recover the p50/p50 homodimer binding activity in nuclear extracts obtained from combination treatment (Figure 5b ).
Neither TAM nor 4-Hydroxytamoxifen (4-OH TAM) exerted a direct effect on either p50/p50 or p50/p65 DNA binding activity
To determine whether TAM or its major metabolite, 4-OH TAM, would directly bind to either NF-kB binding site or NF-kB dimers (p50/p50, p50/p65) leading to conformational changes and a potential decrease in p50/p50 DNA binding activity, nuclear extracts obtained from TNF-a treated cells and combination treated cells were incubated with dierent concentrations of either TAM or 4-OH TAM. EMSA was performed after the end of incubation periods. No changes of DNA binding were seen after incubating the nuclear extracts with TAM and 4-OH TAM (Figure 6 ).
TAM did not enhance the degradation of IkB-a over TNF-a
Degradation of IkB precedes the nuclear translocation of NF-kB complexes and transactivation of NF-kBdependent gene expression. We previously demonstrated that IkB-a is the major component of IkB that is repressive to TNF-a induced activation in VA-13 cells. To determine whether changes in NF-kB DNA binding after TAM and/or TNF-a treatment was due to the degradation of IkB-a, time-course studies to examine IkB-a levels were performed by Western blotting. TNF-a treatment led to a rapid degradation of IkB-a. Within 15 min IkB-a levels were clearly decreased. However, a combination of TAM and TNFa did not further enhance the degradation of IkB-a compared to TNF-a alone. No degradation was seen by treatment of TAM alone (Figure 7 ).
Decreased DNA binding of p50/p50 homodimer is not due to nuclear level of p50 or its precursor, p105
NF-kB DNA binding activity studies showed that the p50/p50 homodimer level was decreased while the p65/ p50 heterodimer complex was increased with TAM and TNF-a combination treatment. Therefore, the levels of p50 and its precursor, p105, were investigated to determine whether the levels of these proteins might contribute to a decrease in p50 binding activity with treatment. Nuclear extracts and cytosolic fractions from VA-13 were prepared after treatment for analysis of p50, p65 and p105 levels by Western blotting (Figure 8 ). The results showed that there was no change in the levels of the p50 and p105 in combination of TAM and TNF-a treatment compared to TNF-a alone. However, the level of p65 protein was increased in the combination treatment.
Discussion
Tamoxifen (TAM) is a non-steroidal antiestrogen drug that is eective in the treatment of breast cancer. However, the mechanisms have not been fully elucidated. It has been demonstrated that transfection of MnSOD cDNA or chromosome 6 into breast cancer cells resulted in suppression of the growth and tumorigenesis (Negrini et al., 1994; Li et al., 1995) .
Our results indicate that TAM-enhances TNF-a induced MnSOD induction in both of the human lung ®broblast cells (VA-13) and human breast cancer cells (MCF-7), indicating that TAM enhancement of TNF-a induced MnSOD expression is not speci®c only to Previous results from our laboratory identi®ed an NF-kB binding site within the second intronic enhancer of the human MnSOD gene (I2E) that is responsive for the induction by TNF-a and IL-b in a manner independent of its orientation (Xu et al., 1999) . Using a reporter assay, we found that the treatment of the cells with cytokines (TNF-a or IL-1b) enhanced the luciferase activity driven by the human MnSOD promoter/enhancer .
In this report, we found that treatment of VA-13 cells with TAM alone had no eect on the NF-kB DNA binding activity. Treatment with TNF-a led to the increase of NF-kB binding activity of both the p50/ p65 heterodimer and p50/p50 homodimer. Interestingly, we found that combination with TAM and TNF-a increased the p50/p65 heterodimer and also markedly reduced the DNA binding activity of p50/p50 homodimer. Because the p50 subunit of NF-kB is synthesized from the N-terminus and C-terminus of p105, which is structurally and functionally similar to the IkB protein, then the interaction of p105 with p65 and p50 could cause the inhibition of nuclear transfer and inactivation of NF-kB (Fan and Maniatis, 1991; Hatada et al., 1993) . Thus, the change of the p105 level in the cytoplasm might be one possibility that could lead to p50/p50 homodimer DNA binding inhibition. However, our data indicate that the cytosolic p105 levels are not altered under the conditions of our experiment, making this mechanism unlikely. NF-kB is normally maintained in an inactive form in the cytoplasm of cells where it is complexed to an inhibitor from the IkB family. Activation of NF-kB is a multi-step process that involves the phosphorylation of the IkB protein, leading to ubiquitination and (c) proteolytic degradation by the 26S proteasome. The degradation of IkB allows translocation of NF-kB to the nucleus, where it regulates gene expression. Since IkB-a is a major IkB family member in the VA-13 cell line, we studied the kinetics of its degradation after treatment and found that TNF-a treatment led to a rapid degradation of IkB-a within 15 min. However, a combination of TAM and TNF-a did not further enhance the degradation of IkB-a compared to TNF-a alone. Moreover, TAM alone did not cause IkB degradation. These results support the data that showed no dierence in the p105 level, and suggest that the reduction of p50/p50 homodimer DNA binding from the combination between TAM and TNF-a is not likely due to a reduced level of p50 subunit protein in the nucleus.
Because Bcl-3 can remove the p50 homodimer from DNA in vitro (Franzoso et al., 1993; Hatada et al., 1992 ), the Bcl-3 level in the nucleus was analysed to determine whether Bcl-3 is associated with the inhibition of p50/p50 homodimer DNA binding. Bcl-3 was not detected in any treatment group by Western blotting (data not shown). We evaluated the possibility that TAM might induce some nuclear protein inhibitors that may form a complex with the p50/p50 homodimer leading to removal or inhibition of p50/p50 binding to DNA. As shown in Figure 6 we did not observe any change in the binding of the p50 homodimer when the nuclear extracts from TAMtreated cells were added to the nuclear extracts from TNF-a treated cells. Dissociating agents, such as DOC, have been shown to release NF-kB from IkB in cytosolic extracts and allow binding to DNA (Baeuerle and Baltimore, 1988) . Treatment of nuclear extracts from stimulated A.E7 cells with DOC led to recovery of p50 DNA binding activity that was equivalent with the binding activity in the resting A.E7 extract (Kang et al., 1992) . In our study, incubation of nuclear extracts from TNF-a treated cells and TAM/TNF-a treated cells with the various concentrations of DOC had no eect on DNA binding or recovery of p50 homodimer binding in the nuclear extracts from TAM/ TNF-a treated cells. Our data suggest that the inhibition of p50 homodimer DNA binding after treatment with the combination of TAM and TNF-a is not likely due to the association of nuclear inhibitor proteins with the p50 homodimer.
Similarly it appears that neither TAM nor its major metabolite, 4-OH TAM has a direct eect on the NFkB binding site or subunit leading to the observed change in DNA binding activity.
The Rel/NF-kB transactivating complexes in cells appear to be homo-and heterodimers involving members of each subclass and dier in their transcriptional activities. The most abundant form of NF-kB in cells is a heterodimer comprised of a p65 subunit, containing both a DNA binding domain and a transcriptional activation domain, plus a p50 subunit, which has a DNA binding domain but no activation domain (Urban and Baeuerle, 1990; Miyamoto and Verma, 1995) . The biological role of p50 homodimer is unclear, but recent evidence suggested that p50/p50 homodimer is capable of acting as a transcriptional repressor. The p50/p50 homodimer was found to act as a repressor of H-2K b gene expression in metastatic tumor cells (Plaksin et al., 1993) . Moreover, the overexpression of p50 can suppress the transactivating eects of p65 at some NF-kB sites (Perkins et al., 1992; Schmitz and Baeuerle, 1991) . TAM itself had no eect on the nuclear levels of p65 and p50. TNF-a treatment led to the increase of both p65 and p50 levels compared to treatment with TAM alone. The combination between TAM and TNF-a showed an increased level of p65 over the control, TAM alone or TNF-a alone (Figure 8 ). These results are consistent with the DNA binding activity after treatment. However, the decrease of the p50 level in the nucleus was not found in the combination between TAM and TNF-a. Thus, the redistribution of the NF-kB p65/p50 and p50/p50 complex is the most likely cause of the increased p65/p50 heterodimer and decrease of the p50/ 50 homodimer DNA binding complex in the TAM and TNF-a combination. Although activation of NF-kB DNA binding is essential for an increased transcription of the human MnSOD gene, numerous studies demonstrated that sustained activation of NF-kB may promote cell death (Abbadie et al., 1993; Lin et al., 1995; Grilli et al., 1996; Grimm et al., 1996; Dumont et al., 1999) . Given substantial data which indicate that increased expression of MnSOD is protective to normal tissues and suppresses tumor growth, redistribution of the NF-kB complex may represent a potential novel strategy to enhance the expression of NF-kB targeted cytoprotective genes.
Materials and methods
Chemicals
Tamoxifen (TAM) and 4-OH TAM were purchased from Sigma chemical company (St. Louis, MO, USA) . TNF-a was purchased from R&D systems (Minneapolis, MN, USA).
Cell culture
An 12E stable transfected VA-13 cell line under the control of the human MnSOD promoter (C7), previously described by Kiningham et al. (2001) , was maintained in BME containing 10% fetal bovine serum, 1% glutamine, 1% antibiotics (penicillin/streptomycin), and 400 mg/ml of geneticin. MCF-7 cell line was maintained in DMEM containing 10% fetal bovine serum, 1% glutamine, 1% antibiotics (penicillin/streptomycin), 1% nonessential amino acid, 1 mM sodium pyruvate. Cells were cultured at 378C in a humidi®ed incubator containing 5% CO 2 .
Luciferase activity
For experiments using C7, 1610 5 of cells were plated in a 24 well plate. After 72 h, cells were treated with TAM for 24 h followed by 200 U/ml TNF-a for 12 h. In preliminary experiments, TAM and TNF-a concentrations were optimized to maximize luciferase activity without causing cytotoxicity. After treatment, cells were washed with PBS twice and lysed in 100 ml of reporter lysis buer (Promega). Luciferase activity was measured using the Luciferase assay system (Promega) according to the manufacturer's instructions in a TD-20/20 luminometer. All luciferase activities were normalized to protein concentration, which was determined by a colorimetric assay (Biorad Laboratories, Richmond, CA, USA).
Northern analysis
After incubation with TAM for 24 h, followed by TNF-a treatment for 6 h, total RNA was isolated by the guanidine isothiocyanate method. 30 mg of total RNA was detected for MnSOD level as previously described .
Preparation of cytoplasmic fraction and nuclear extract
Cells were plated at a density of 1610 6 cells/150 mm dish. After treatment, nuclear extract and cytoplasmic fractions were isolated as described by Dignam and Roeder (1983) . Protein concentration was determined by a colorimetric assay (Biorad Laboratories, Richmond, CA, USA).
Western analysis
For protein analysis, total cell lysate, cytoplasmic fraction, membrane fraction, or nuclear extracts were separated by 10% SDS±PAGE gel electrophoresis and electrotransferred to a nitrocellulose membrane (Schleicher and Schuell, Keene, NH, USA). After transfer, membranes were blocked in Blotto (10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Tween 20, and 5% nonfat dried milk) at room temperature for 1 h. To detect MnSOD speci®c proteins, the membrane was incubated with a MnSOD antibody (1 : 5000) raised against human kidney MnSOD (kindly provided from Dr Larry Oberley at the University of Iowa, USA) at room temperature for 2 h. To detect p50, p65, p105 (1 : 1000), and Bcl-3 (1 : 200), the membranes were incubated with speci®c antibody (Santa Cruz Biotechnology, CA, USA), at room temperature for 2 h. After incubation with primary antibody, membranes were washed twice with TBST (10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Tween 20) and then incubated with horseradish peroxidase-conjugated goat antirabbit IgG antibody (1 : 5000) (Santa Cruz Biotechnology, CA, USA) at room temperature for 1 h. The membranes were washed three times with TBST followed by one rinse of TBS (10 mM Tris-HCl, 150 mM NaCl, pH 8.0). Protein bands were visualized by the enhanced chemiluminescence detection system (ECL, Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Electrophoretic mobility shift assay
Oligonucleotides corresponding to C/EBP, NF-1 and NF-kB were either purchased from Life Technologies or Santa Cruz Biotechnology: C/EBP 5'-TGCAGATTGCGCAATCTGCA-3' NF-1 5'-CAGTTGTGAAAGTACTTCC-3' NF-kB 5'-AG-TTGAGGGGACTTTCCCAGG-3'.
The oligonucleotides were annealed to their complementary strand and end radiolabeled with 32 P using T4-polynucleotide kinase (New England Biolab, Beverly, MA, USA) and [g-32 P] ATP. The labeled probes were then puri®ed on a 20% native page gel and the binding reaction was performed as previously described . For supershift assay, the nuclear extract was preincubated with anti-p50 or anti-p65 antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) for 1 h at room temperature before the binding reaction was performed.
Statistical analysis
All experiments were replicated in triplicate and representative ®ndings are shown. Analysis of variance was performed for multiple samples and statistical signi®cance was determined by using ANOVA.
